Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22339813 | 0.79 | CYP2A6 (0.50) | ALDH1A1CYP3A4 | |
| SCHEMBL20867730 | 0.78 | ATM (0.44) | ATMDDB1CRBNALDH1A1NOTUM | |
| SCHEMBL19398118 | 0.72 | ATM (0.43) | ATMDDB1CRBNALDH1A1NOTUM | |
| SCHEMBL17911735 | 0.71 | MAPK14 (0.46) | ATMALDH1A1NOTUMMAPTCYP1A2 | |
| SCHEMBL16658997 | 0.71 | ATM (0.41) | ATMDDB1CRBNALDH1A1NOTUM | |
| SCHEMBL10183098 | 0.71 | HSP90AA1 (0.41) | ALDH1A1CYP3A4LOX | |
| SCHEMBL17918817 | 0.70 | GSK3A (0.43) | ATMALDH1A1NOTUMMAPTMEN1 | |
| SCHEMBL1127502 | 0.70 | ATM (0.48) | ATMDDB1CRBNALDH1A1NOTUM | |
| SCHEMBL289208 | 0.69 | ATM (0.40) | ATMDDB1CRBNALDH1A1NOTUM | |
| SCHEMBL28612089 | 0.68 | ATM (0.39) | ATMDDB1CRBNALDH1A1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-7906228-B2 | Compounds for electronic material and organic electronic device using the same | GRACEL DISPLAY INC. (KR) | 2011-03-15 | — | — | US | disclosed |
| US-7906228-B2 | Compounds for electronic material and organic electronic device using the same | GRACEL DISPLAY INC. (KR) | 2011-03-15 | — | — | US | disclosed |
| US-20090288707-A1 | Novel compounds for electronic material and organic electronic device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-26 | — | — | US | disclosed |
| US-20090288707-A1 | Novel compounds for electronic material and organic electronic device using the same | GRACEL DISPLAY INC. (KR) | 2009-11-26 | — | — | US | disclosed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
| WO-2007032028-A1 | THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188810-A1 | HETEROARYL INHIBITORS OF PAD4 | PADI4, PADI1, PADI6 | ATM 1292/4885DDB1 34/4885CRBN 1318/4885 |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | ATM 1200/4885DDB1 1915/4885CRBN 563/4885 |
| US-11198681-B2 | Heteroaryl inhibitors of PAD4 | PADI4, PADI1, PADI6 | ATM 1292/4885DDB1 34/4885CRBN 1318/4885 |
| US-20090288707-A1 | Novel compounds for electronic material and organic electronic device using the same | OCIAD1, OCIAD2, ORMDL3 | ATM 4102/4885DDB1 3891/4885CRBN 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.